biological_process

BLOOD-BRAIN BARRIER

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BLOOD-BRAIN BARRIER: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2267Connections

11Hypotheses

3Analyses

50Outgoing

50Incoming

9Experiments

10Debates

No summary available yet.

View on Wiki →

No AI portrait yet

🧬 Biological Process Info

Name	BLOOD-BRAIN BARRIER
Related Diseases	ALZHEIMER'S DISEASE

Pathway Diagram

graph TD
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"causes"| PARP1["PARP1"]
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"regulates"| CLDN5["CLDN5"]
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"causes"| ENDOTHELIAL["ENDOTHELIAL"]
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"causes"| STROKE["STROKE"]
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"impairs"| MICROGLIA["MICROGLIA"]
    BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"] -->|"impairs"| ENDOTHELIAL_1["ENDOTHELIAL"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated"| BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"]
    MICROGLIA_2["MICROGLIA"] -->|"associated"| BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"]
    NEURODEGENERATION["NEURODEGENERATION"] -->|"associated"| BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"]
    NEUROINFLAMMATION["NEUROINFLAMMATION"] -->|"associated"| BLOOD_BRAIN_BARRIER["BLOOD-BRAIN BARRIER"]
    style BLOOD_BRAIN_BARRIER fill:#5d4400,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (226)

Target	Relation	Type	Str
Brain Homeostasis	associated_with	process	0.95
Biologics Delivery	inhibits	mechanism	0.95
Cerebral Endothelial Cells	component_of	cell_type	0.95
Alzheimer'S Disease	associated_with	disease	0.95
Cognitive Decline	causes	phenotype	0.90
Brain Hemorrhage	risk_factor_for	phenotype	0.90
Neuroinflammation	associated_with	process	0.90
Neuronal Function	involved_in	phenotype	0.90
Neurodegeneration	involved_in	disease	0.90
Amyloid Beta	transports	protein	0.85
Drug Permeability	involved_in	phenotype	0.85
AMYLOID-BETA	regulates	protein	0.85
Brain Arteriovenous Malformations	biomarker_for	disease	0.85
Neurotoxic Compounds Clearance	mediates	process	0.80
Neurovascular Coupling	associated_with	process	0.80
neurodegeneration	mediates	process	0.80
Compound Penetration	inhibits	phenotype	0.78
Amyloid β-targeted monoclonal antibodies	modulates	drug	0.75
hippocampus	regulates	brain_region	0.70
TKI accumulation	inhibits	process	0.70
Cerebral edema	causes	disease	0.70
Alzheimer's disease	associated_with	disease	0.70
Complement	interacts_with	pathway	0.55
Pyroptosis	interacts_with	pathway	0.55
Mtor	interacts_with	pathway	0.55
Mitophagy	interacts_with	pathway	0.55
Autophagy	interacts_with	pathway	0.55
Apoptosis	interacts_with	pathway	0.55
Ubiquitin-Proteasome	interacts_with	pathway	0.55
NLRP3	co_discussed	entity	0.50
CHOLESTEROL	co_discussed	entity	0.50
CYP46A1	co_discussed	entity	0.50
CORTEX	co_discussed	entity	0.50
SMPD1	co_discussed	entity	0.50
HYPOTHALAMUS	co_discussed	entity	0.50
THALAMUS	co_discussed	entity	0.50
T CELL	co_discussed	entity	0.50
T CELLS	co_discussed	entity	0.50
NECROPTOSIS	co_discussed	entity	0.50
SCHIZOPHRENIA	co_discussed	entity	0.50
HUNTINGTON	co_discussed	entity	0.50
MITOCHONDRIAL DYSFUNCTION	co_discussed	entity	0.50
PROTEOSTASIS	co_discussed	entity	0.50
OCLN	co_discussed	entity	0.50
EXCITOTOXICITY	co_discussed	entity	0.50
MULTIPLE SCLEROSIS	co_discussed	entity	0.50
ISCHEMIA	co_discussed	entity	0.50
SENESCENCE	co_discussed	entity	0.50
TNF	co_discussed	entity	0.50
MS	co_discussed	entity	0.50

Incoming (2041)

Source	Relation	Type	Str
NEURODEGENERATIVE DISEASES	therapeutic_target	gene	1.00
INFLAMMATION	therapeutic_target	gene	1.00
Inflammation	activates	disease	1.00
Stroke	therapeutic_target	disease	1.00
Als	inhibits	disease	1.00
MICROGLIA	therapeutic_target	gene	1.00
Aging	therapeutic_target	disease	1.00
ALZHEIMER	activates	gene	1.00
OXIDATIVE STRESS	therapeutic_target	gene	1.00
NEURODEGENERATION	therapeutic_target	gene	1.00
Als	activates	disease	1.00
Inflammation	associated_with	disease	1.00
AMYLOID	activates	gene	1.00
NEUROINFLAMMATION	associated_with	gene	1.00
Neuroinflammation	activates	disease	1.00
INFLAMMATION	activates	gene	1.00
NEUROINFLAMMATION	therapeutic_target	gene	1.00
Neurodegeneration	activates	disease	1.00
CYTOKINES	activates	gene	1.00
PARKINSON'S DISEASE	therapeutic_target	gene	1.00
APOPTOSIS	activates	gene	1.00
AMYLOID	therapeutic_target	gene	1.00
MICROGLIA	activates	gene	1.00
INFLAMMATION	inhibits	gene	1.00
NEURODEGENERATIVE DISORDERS	therapeutic_target	gene	1.00
Als	associated_with	disease	1.00
Neuroinflammation	associated_with	disease	1.00
Alzheimer	associated_with	disease	1.00
APOPTOSIS	therapeutic_target	gene	1.00
Inflammation	inhibits	disease	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
ALZHEIMER	associated_with	gene	1.00
OXIDATIVE STRESS	activates	gene	1.00
Alzheimer	activates	disease	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
PARKINSON	therapeutic_target	gene	1.00
ALZHEIMER	therapeutic_target	gene	1.00
Neuroinflammation	therapeutic_target	disease	1.00
Inflammation	therapeutic_target	disease	1.00
NEURODEGENERATION	activates	gene	1.00
NEUROINFLAMMATION	activates	gene	1.00
Parkinson	therapeutic_target	disease	1.00
ALZHEIMER'S DISEASE	therapeutic_target	gene	1.00
STROKE	therapeutic_target	gene	1.00
EXOSOMES	therapeutic_target	gene	1.00
Als	therapeutic_target	disease	1.00
Neurodegeneration	therapeutic_target	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
TAU	activates	gene	1.00
Multiple Sclerosis	therapeutic_target	disease	1.00

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Soluble PDGFRβ as a Peripheral Indicator of Pericyte-Mediate	0.705	-	What blood-brain barrier permeability ch
Optogenetic viral vector delivery via tFUS-mediated blood-br	0.622	Alzheimer's disease	Circuit-level neural dynamics in neurode
Blood-Brain Barrier SPM Shuttle System	0.533	neurodegeneration	Neuroinflammation resolution mechanisms
GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to R	0.513	neuroinflammation	Why do TAM receptors protect against neu
TREM2-Mediated Microglial Dysfunction Drives Tau-Induced Blo	0.499	neuroscience	Circuit-level neural dynamics in neurode

Blood-Brain Barrier Disruption Enabling Peripheral Inflammat	0.430	neurodegeneration	How does APOE4 mechanistically increase
Transferrin-Alectinib Conjugation Enhances Blood-Brain Barri	0.406	molecular biology	Does Alectinib truly bind C1q directly w
tight-junction remodeling is the actionable driver in: Blood	0.362	neurodegeneration	Blood-brain barrier permeability changes
endothelial transcytosis defines the therapeutic window for:	0.357	neurodegeneration	Blood-brain barrier permeability changes
plasma GFAP separates causal from compensatory states in: Bl	0.346	neurodegeneration	Blood-brain barrier permeability changes
Blood-Brain Barrier Metabolite Transporter Enhancement for D	0.272	metabolomics	Metabolomic signatures of neurodegenerat

Mentioning Analyses (3)

Scientific analyses that reference this entity

Are age-related static epigenetic patterns pathogenic or protective compensatory

epigenetics | 2026-04-15 | 0 hypotheses

Senescent cell clearance as neurodegeneration therapy

neurodegeneration | 2026-04-04 | 7 hypotheses Top: 0.769

Neuroinflammation resolution mechanisms and pro-resolving mediators

neurodegeneration | 2026-04-01 | 0 hypotheses

Experiments (9)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - ALOX15 overexpression in healthy astrocytes should be protectiv	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - Compare uptake with/without magnetic particles using tight junc	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$120,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Blood-Based Biomarker Panel for Early AD Detection	clinical	Alzheimer's Disease	0.400	0.50	cell_line	proposed	$220,000
Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur	validation	Neurodegeneration	0.400	0.50	cell_line	proposed	$130,000
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Progranulin Replacement Therapy for FTD — Vector Development and Valid	clinical	ALS	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies [PMID:40447280]	Russell CD, Goeldner-Thompson S, Smith E	J Infect Dis	2025	1
An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766]	Huang Q, Chan KY, Wu J, Botticello-Romer	Science	2024	1
Targeting the transferrin receptor to transport antisense oligonucleotides acros [PMID:39141703]	Barker SJ, Thayer MB, Kim C, Tatarakis D	Sci Transl Med	2024	1
Blood-brain barrier transport using a high affinity, brain-selective VNAR antibo [PMID:33241587]	Stocki P, Szary J, Rasmussen CLM, Demydc	FASEB J	2021	1
Transferrin receptor 1 in cancer: a new sight for cancer therapy. [PMID:30034931]	Shen Y, Li X, Dong D, Zhang B, Xue Y, Sh	American journal of cancer res	2018	1
Cadmium exposure is associated with impaired ovarian function: Potential role of [PMID:41548307]	["Li J", "Wang Y", "Huang Y", "Li N", "Z	Journal of hazardous materials	2026	0
A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456]	Yesiltepe M, Metkar S, Yin T, Chakrabort	The Journal of biological chem	2026	0
Early hypoxia-induced secretome remodeling reveals adaptive mechanisms and bioma [PMID:41699623]	Wu Q, Jiang Y, Peng L, Dang Y, You C, Li	Molecular brain	2026	0
MITF programs macrophage iron homeostasis to drive gut-liver inflammatory axis i [PMID:41832955]	Han D, Han L, Kang L, Liu J, Zhang N, Tu	Cell reports	2026	0
Crossing the blood-brain barrier: emerging therapeutic strategies for neurologic [PMID:39862873]	Pedder JH, Sonabend AM, Cearns MD	Lancet Neurol	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal gangli [PMID:40345829]	Shi, Sato, Takahashi, Ohno-Ohishi, Muray	Life science alliance	2025	0
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegen [PMID:40468412]	Karunakaran Devi Krishna Priya; Ley Make	Molecular neurodegeneration	2025	0
AAV2-driven endothelin induces chronic reduced retinal blood flow/retinal gangli [PMID:40345829]	Unknown	Life science alliance	2025	0
Ferrostatin-1 alleviates experimental cerebral malaria by regulating immune cell [PMID:41422632]	Yao S, Zhou X, Liao T, Yao C, Sun M, Gou	International journal for para	2025	0
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegen [PMID:40468412]	Karunakaran DKP, Ley M, Guo J, Khatri A,	Molecular neurodegeneration	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Dietary Iron Deficiency in Adult Mice Increases Brain Uptake of High-Affinity, A [PMID:41299828]	Kostrikov S, Johnsen KB, Burkhart A, Hel	Journal of neurochemistry	2025	0
A covalent peptide-based lysosome-targeting protein degradation platform for can [PMID:39910101]	Xiao Y, He Z, Li W, Chen D, Niu X, Yang	Nature communications	2025	0
Blood-brain barrier biomarkers. [PMID:38797540]	Zapata-Acevedo JF, Mantilla-Galindo A, V	Adv Clin Chem	2024	0

Debates (10)

Multi-agent debates referencing this entity

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

closed · Rounds: 4 · Score: 0.75 · 2026-04-16

The debate assumed static 5-hydroxymethylcytosine patterns in aging neurons are

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Senescent cell clearance as neurodegeneration therapy

closed · Rounds: 3 · Score: 0.95 · 2026-04-04

What are the mechanisms underlying neuroinflammation resolution mechanisms and p

closed · Rounds: 5 · Score: 0.95 · 2026-04-01

Related Research

Hypotheses and analyses mentioning BLOOD-BRAIN BARRIER in their description or question text

Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult

Score: 0.430 · neurodegeneration · 2026-04-21

## Mechanistic Overview Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult starts from the claim tha

Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Tra

Score: 0.406 · molecular biology · 2026-04-21

## Mechanistic Overview Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Transferrin Recepto

tight-junction remodeling is the actionable driver in: Blood-brain barrier perme

Score: 0.362 · neurodegeneration · 2026-04-26

The gap can be tested by treating tight-junction remodeling as an upstream driver rather than a passive correlate. If tr

endothelial transcytosis defines the therapeutic window for: Blood-brain barrier

Score: 0.357 · neurodegeneration · 2026-04-26

The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dos

plasma GFAP separates causal from compensatory states in: Blood-brain barrier pe

Score: 0.346 · neurodegeneration · 2026-04-26

A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. Th

Blood-Brain Barrier Metabolite Transporter Enhancement for Diagnostic and Therap

Score: 0.272 · metabolomics · 2026-04-25

## Mechanistic Overview The hypothesis centers on SLCO2A1 (encoded by the solute carrier organic anion transporter fami